Revalesio is focused on the development of a new class of novel therapeutics for the treatment of inflammatory diseases using our proprietary charge-stabilized nanostructure (CSN) technology.

Revalesio’s novel therapeutics act in a broad-based manner to change the responsiveness of cells to inflammatory stimuli. Our products alter whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the G protein-coupled receptors and secretion of cytokines, chemokines and adhesion molecules. Revalesio’s CSN therapeutics have displayed significant efficacy in multiple pre-clinical studies in a variety of therapeutic models. A remarkable absence of toxicity has been demonstrated in pre-clinical inhalation, intravenous and genotoxicity studies. Visit our pipeline to learn more about applications for our technology.